Abstract
Nephroangiosclerosis (NAS) is a major cause of progressive renal insufficiency. Hypertension is very important in the causation of NAS but other factors such as race, age, metabolic variables, and genetics play a pathogenic and prognostic role. A multifactorial treatment strategy, including antihypertensive, lipid-lowering and anti-platelet agents, could improve cardiovascular and renal outcomes in patients with vascular nephropathy.
MeSH terms
-
Animals
-
Antihypertensive Agents / therapeutic use
-
Arteriosclerosis / drug therapy*
-
Arteriosclerosis / etiology
-
Arteriosclerosis / genetics
-
Arteriosclerosis / physiopathology
-
Atherosclerosis / physiopathology
-
Dyslipidemias / physiopathology
-
Humans
-
Hypertension / physiopathology
-
Hypolipidemic Agents / therapeutic use
-
Kidney Diseases / drug therapy*
-
Kidney Diseases / etiology
-
Kidney Diseases / genetics
-
Kidney Diseases / physiopathology
-
Nephrosclerosis / etiology
-
Platelet Aggregation Inhibitors / therapeutic use
Substances
-
Antihypertensive Agents
-
Hypolipidemic Agents
-
Platelet Aggregation Inhibitors